{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:48:07Z","timestamp":1783493287835,"version":"3.55.0"},"reference-count":54,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"31","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Use of cytotoxic chemotherapy at end-of-life (EOL) is associated with adverse quality of life, increased health care utilization, and lower hospice rates. Although EOL cytotoxic chemotherapy use has declined in recent years, EOL novel (immunotherapy and targeted therapy) use has increased. The association between use of novel therapies at EOL and health care utilization has not been widely studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We identified patients within SEER-Medicare who had part D coverage (excluding those with Medicare Advantage) age 66 years and older, and breast, colorectal, lung, prostate, bladder, cervical, kidney, liver, ovarian, pancreatic, melanoma, or uterine cancer. Patients were diagnosed between 2005 and 2019 and died between 2015 and 2020. We analyzed associations between EOL systemic anticancer therapy (SACT) use (overall and by subtype), and health care utilization in the last 30 days of life (emergency department [ED], hospitalization, intensive care unit [ICU], and inpatient death), and hospice with multivariable regression, controlling for sociodemographic and cancer covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 315,089 beneficiaries, 23,970 (7.6%) received SACT within 30 days of death. The breakdown by type was cytotoxic therapy 50.6%, immunotherapy 20.8%, targeted therapy 18%, and combination therapies 10.6%. After adjusting for covariates, any SACT use at EOL was associated with higher ED use (odds ratio [OR], 3.05 [95% CI, 2.95 to 3.15]), hospital admissions (OR, 2.64 [95% CI, 2.56 to 2.72]), ICU admission (OR, 1.78 [95% CI, 1.72 to 1.83]), hospital death (OR, 2.02 [95% CI, 1.96 to 2.08]), and lower hospice use (OR, 0.51 [95% CI, 0.50 to 0.53]) compared with no SACT. All subtypes of SACT were individually associated with higher health care utilization and lower hospice use (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>All subtypes of SACT use were associated with markers of worse-quality EOL care. These data can inform decisions for current care guidelines and efforts to reduce overutilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-00530","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:59:21Z","timestamp":1758916761000},"page":"3391-3402","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality"],"prefix":"10.1200","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-3542","authenticated-orcid":true,"given":"Maureen E.","family":"Canavan","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Cheng","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4390-7641","authenticated-orcid":true,"given":"Jenny Jing","family":"Xiang","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-4453","authenticated-orcid":true,"given":"John Kent","family":"Lin","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-6607","authenticated-orcid":true,"given":"David","family":"Hui","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-1139","authenticated-orcid":true,"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9425-8114","authenticated-orcid":true,"given":"Nico","family":"Nortje","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-7922","authenticated-orcid":true,"given":"Ravin","family":"Ratan","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-8952","authenticated-orcid":true,"given":"Nathan","family":"Cherny","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-395X","authenticated-orcid":true,"given":"Trinh","family":"Pham","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8700-2767","authenticated-orcid":false,"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangong","family":"Niu","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4507-4502","authenticated-orcid":true,"given":"Kerin B.","family":"Adelson","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.30_suppl.303"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000678"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.03.28"},{"key":"e_1_3_7_5_2","first-page":"1","article-title":"A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?","volume":"10","author":"Cherney NI","year":"2025","unstructured":"Cherney NI, Nortje N, Kelly R, et al: A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed? ESMO Open 10:1-16, 2025","journal-title":"ESMO Open"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4666"},{"key":"e_1_3_7_7_2","article-title":"Novel systemic anticancer treatments and health services use at the end of life among adults with cancer","author":"Javaid Iqbal RM","unstructured":"Javaid Iqbal RM, Quinn KL, Booth CM, et al: Novel systemic anticancer treatments and health services use at the end of life among adults with cancer. J Clin Oncol 10.1200\/JCO-24-02816 [epub ahead of print on June 4, 2025]","journal-title":"J Clin Oncol"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02067"},{"key":"e_1_3_7_9_2","first-page":"e1726","article-title":"Utilization of systemic therapy in patients with cancer near the end of life in the pre- versus postimmune checkpoint inhibitor eras","volume":"17","author":"Ali RK","year":"2021","unstructured":"Ali RK, Chennupati S, Fedorenko C, et al: Utilization of systemic therapy in patients with cancer near the end of life in the pre- versus postimmune checkpoint inhibitor eras. JCO Oncol Pract 17:e1726-e1737, 2021","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112912"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4661"},{"key":"e_1_3_7_12_2","unstructured":"National Cancer Institute: Base FFS claims files. 2024. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/medicare\/claims.html"},{"key":"e_1_3_7_13_2","volume-title":"Surveillance Research Program SEER Website Tool Division of Cancer Control and Population Sciences. Version 1.26.1","author":"Cancer Medications Enquiry Database (CanMED)","year":"2025","unstructured":"Cancer Medications Enquiry Database (CanMED): Surveillance Research Program SEER Website Tool Division of Cancer Control and Population Sciences. Version 1.26.1. National Cancer Institute, 2025. https:\/\/seer.cancer.gov\/oncologytoolbox\/canmed\/"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgaa002"},{"key":"e_1_3_7_15_2","unstructured":"NQF: Proportion of Patients Who Died From Cancer With More Than One Emergency Department Visit in the Last 30 Days of Life. NQF 02112012"},{"key":"e_1_3_7_16_2","unstructured":"NQF: Proportion With More Than One Hospitalization in the Last 30 Days of Life. NQF 02122009"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.03.011"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/00131644241278928"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.12.240"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.2364"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1129"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.136"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102561"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-021-00731-4"},{"key":"e_1_3_7_26_2","unstructured":"Patient Safety Network: National Voluntary Consensus Standards for Patient Safety Measures: A Consensus Report. June 27 2012. https:\/\/psnet.ahrq.gov\/issue\/national-voluntary-consensus-standards-patient-safety-measures-consensus-report"},{"key":"e_1_3_7_27_2","unstructured":"FNQ: Proportion Admitted to the ICU in the Last 30 Days of Life. NQF 02132009"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02180"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.18604"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30496-6"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7233.469"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0149"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7408.195"},{"key":"e_1_3_7_34_2","first-page":"209","article-title":"How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally III cancer patients? A systematic review","volume":"13","author":"Chow E","year":"2001","unstructured":"Chow E, Harth T, Hruby G, et al: How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally III cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 13:209-218, 2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327481502200415"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy178"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0926"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00163"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27946-5"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8687"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.587"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119848148"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11092"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1534"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216307082476"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.6503"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.13978"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014661"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-018-0339-8"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-10-1095"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.8_suppl.228"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2019-001770"},{"key":"e_1_3_7_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12161"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T22:00:38Z","timestamp":1761775238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1200\/JCO-25-00530"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00530","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}